Down 70%, Novo Nordisk Bets $3.9 Billion to Outrun Eli Lilly in the Weight-Loss Race Oct 2, 2026 Life Science
AbbVie vs. Bristol Myers Squibb: A Clash Between Growth Premium and Value Trap Oct 1, 2026 Life Science
Lilly and Viking Just Showed the Obesity Market’s Next Phase — and It’s Not About Pounds Sep 30, 2026 Life Science
AstraZeneca to Invest $2 Billion in Summit Therapeutics, Backing China-Licensed Cancer Drug Sep 29, 2026 Life Science
ByteDance’s Anew Labs Emerges With $1.5B Valuation, Stirring New Questions Over AI Drug Discovery Sep 25, 2026 Life Science
Positive VK2735 Clinical Data: Can Viking Therapeutics Displace Eli Lilly and Novo Nordisk? Sep 23, 2026 Life Science
Iambic Therapeutics Files for U.S. IPO, Adding Another AI Drug-Discovery Startup to Nasdaq Pipeline Sep 22, 2026 Life Science, Technology
Can Novo Nordisk’s Anthropic Partnership Drive an AI-Powered Turnaround? Sep 16, 2026 Life Science, Technology
Eli Lilly Ramps Up Acquisitions to Diversify Beyond Weight-Loss Drug Dominance Sep 15, 2026 Life Science
Amgen vs. Vertex Pharmaceuticals: Value Stability vs. High-Growth Biotech Investment Plays Sep 14, 2026 Life Science
Novo Nordisk Scores Pediatric Weight-Loss Trial Win, Unlocking Contrarian Investment Value Sep 11, 2026 Life Science
